Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma

100%
Kruczała M., Grela-Wojewoda A., Ziobro M.
OncoReview
|
2017
|
vol. 7
|
issue 3
139-143
EN
A major progress has been made in the systemic treatment of advanced melanoma over the last few years. Targeted therapy has proven highly active, which is reflected in the response rate as well as progression-free survival and overall survival times. The paper aims to summarize the current knowledge on the available BRAF and MEK inhibitors.
2
Publication available in full text mode
Content available

Everolimus – effectively reverses acquired resistance on endocrine therapy of patients with advanced breast cancer. A case report

100%
Grela-Wojewoda A., Kruczała M., Cedrych I.
OncoReview
|
2014
|
vol. 4
|
issue 3
A117-120
EN
Breast cancer is the most common malignancy among women in Poland. Endocrine therapy is the first line of treatment in hormone-receptor-positive advanced breast cancer. Progression during endocrine therapy is unavoidable. Administration of mTOR inhibitor gives a chance of reversing the acquired resistance. This paper presents a case report of a patient with metastatic breast cancer successfully treated with everolimus added to endocrine therapy.
3
Publication available in full text mode
Content available

Advanced skin melanoma – systemic treatment

100%
Kruczała M., Ziobro M., Grela-Wojewoda A., Cedrych I.
OncoReview
|
2015
|
vol. 5
|
issue 3
A133-138
EN
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcomes. This review paper presents current knowledge on systemic treatment of advanced melanoma, including treatment availability in Poland.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.